Avior Wealth Management LLC Has $293,000 Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Avior Wealth Management LLC lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 33.9% during the fourth quarter, Holdings Channel reports. The firm owned 4,670 shares of the company’s stock after purchasing an additional 1,183 shares during the quarter. Avior Wealth Management LLC’s holdings in Vaxcyte were worth $293,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Ellsworth Advisors LLC raised its position in shares of Vaxcyte by 2.6% during the fourth quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock worth $506,000 after purchasing an additional 207 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vaxcyte by 0.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock worth $3,211,000 after purchasing an additional 296 shares during the period. Strs Ohio raised its position in shares of Vaxcyte by 3.9% during the fourth quarter. Strs Ohio now owns 10,700 shares of the company’s stock worth $671,000 after purchasing an additional 400 shares during the period. Alps Advisors Inc. raised its position in shares of Vaxcyte by 0.6% during the third quarter. Alps Advisors Inc. now owns 69,305 shares of the company’s stock worth $3,533,000 after purchasing an additional 426 shares during the period. Finally, Keybank National Association OH raised its position in shares of Vaxcyte by 12.9% during the third quarter. Keybank National Association OH now owns 4,565 shares of the company’s stock worth $233,000 after purchasing an additional 522 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $63.92, for a total transaction of $958,800.00. Following the completion of the sale, the chief executive officer now owns 375,814 shares in the company, valued at approximately $24,022,030.88. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, SVP Elvia Cowan sold 11,678 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $74.08, for a total transaction of $865,106.24. Following the completion of the sale, the senior vice president now owns 12,480 shares in the company, valued at approximately $924,518.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $63.92, for a total value of $958,800.00. Following the sale, the chief executive officer now owns 375,814 shares of the company’s stock, valued at approximately $24,022,030.88. The disclosure for this sale can be found here. Insiders have sold 101,577 shares of company stock worth $6,940,475 over the last 90 days. 3.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on PCVX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Needham & Company LLC reissued a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a research report on Wednesday, April 10th. Finally, Bank of America upped their price target on Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte currently has an average rating of “Buy” and a consensus price target of $78.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX opened at $60.83 on Friday. The business’s 50-day moving average price is $69.39 and its two-hundred day moving average price is $60.93. Vaxcyte, Inc. has a one year low of $41.57 and a one year high of $82.04.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter in the previous year, the firm posted ($0.73) earnings per share. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.18 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.